Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease (NCT05843552)
๐ฉบ Plain-English Summary (8th-Grade Level)
This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.
Who can join: Review the eligibility criteria below.
Location: University of Minnesota โ Minneapolis, Minnesota
Age range: 18 Years to 80 Years
๐งช Interventions in This Study
- no intervention (OTHER)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University of Minnesota โ Minneapolis, Minnesota
๐ Contact the Study Coordinator
Phone: (612) 626-2436
Email: rvkartha@umn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gaucher Disease
- A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) โ Durham, North Carolina
- Long Term Follow-Up for Safety of AVR-RD-02 โ Iowa City, Iowa
- International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry โ Phoenix, Arizona
- A Long-term Follow-up Study of Gaucher Disease โ Durham, North Carolina
- Gaucher Disease Outcome Survey (GOS) โ Lexington, Massachusetts
Explore by condition: All Gaucher Disease clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.